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Nanotechnology has found its potential in every possible field of science and engineering. It offers a plethora of options to design
tools at the nanometer scale, which can be expected to functionmore effectively thanmicro- andmacrosystems for specific applica-
tions. Although the debate regarding the safety of synthetic nanomaterials for clinical applications endures, it is a promising tech-
nology due to its potential to augment current treatments. Various materials such as synthetic polymer, biopolymers, or naturally
occurring materials such as proteins and peptides can serve as building blocks for adaptive nanoscale formulations. The choice of
materials depends highly on the application. We focus on the use of nanoparticles for the treatment of degenerative cartilage dis-
eases, such as osteoarthritis (OA). Current therapies for OA focus on treating the symptoms rather thanmodifying the disease. The
usefulness of OA disease modifying drugs is hampered by side effects and lack of suitable drug delivery systems that target,
deliver, and retain drugs locally. This challenge can be overcome by using nanotechnological formulations. We describe the dif-
ferent nanodrug delivery systems and their potential for cartilage repair. This paper provides the reader basal understanding of
nanomaterials and aims at drawing new perspectives on the use of existing nanotechnological formulations for the treatment of
osteoarthritis.
1. Introduction
Osteoarthritis is caused by a multitude of factors, which have
not been completely explored and understood. However, the
gathered clinical observations and research data on OA
during the last decades help to understand some of the pro-
cesses involved in the etiology, development, and progression
of the disease. The perception that OA is a cartilage-spe-
cific disorder is slowly changing towards the view that it is
a disorder of the whole joint [2–4]. During OA, apart from
articular cartilage, abnormal physiological changes are ob-
served in subchondral bone, synovial membrane, and con-
nective tissue (Figure 1) [5]. Despite the accumulating know-
ledge of OA, there is currently no US Food and Drug admini-
stration approved systemic drug able to modify the disease
progression. The clinical practice is, therefore, based on sym-
ptomatic treatment aimed at alleviation of pain and surgical
replacement of joints with end-stage OA [6]. Drugs that
target specific elements of OA disease progression have
been developed, but are associated with severe side effects
preventing it from routine clinical use.
Measures of reversing or regenerating the degraded
cartilage are being extensively studied, but largely remain
in a preclinical phase [7, 8]. Accumulating knowledge of
OA disease mechanisms suggests that abnormal activation
of signaling networks plays a leading role in cartilage degra-
dation [9–11] along with other factors such as mechanical
loading [12]. In order to rescue cartilage from the catabolic
effects of these pathways, the balance of anabolic/catabolic
pathwaysmust be restored [11].Many targets to establish this
balance have been previously described [13–15]. Drugs that
are specific for these various targets have also been reported
[16]. However, the therapeutic success of these disease modi-
fying drugs mainly depends on the delivery route, as most of
these drugs are associated with adverse side effects that are
not acceptable for nonlife threatening diseases [1]. Local
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Figure 1: Healthy (on left) and Osteoarthritic joints [1]. Joint components such as articular cartilage, subchondral bone, and synovial mem-
brane show abnormal morphology in osteoarthritic joint. Reproduced with permission from Elsevier.
delivery of these drugs using nanoscale carriers might prove
essential in circumventing the systemic side effects caused by
these drugs. This paper details the potential of nanopartic-
ulate systems for the use in local delivery of osteoarthritis
drugs in synovial joints. We describe and discuss the advan-
tages and disadvantages of using micelles (2), liposomes (3),
dendrimers (4), and other nanoparticles (5) for intra-arti-
cular delivery of drugs in OA, as well as the drugs that can be
combined with these vehicles (6).
Nanomaterials are used in the field of medicine in dif-
ferent configurations for a variety of applications, including
drug delivery [17], imaging [18], and diagnostics. Cancer
treatments have benefited highly from using nanotechnology
as many anticancer drugs are toxic by nature, which can
cause severe side effects by acting in healthy tissues upon sys-
temic administration [19]. This necessitated the use of nano-
scale delivery vehicles in cancer treatment to circumvent
these drug side-effects. Nanoscale delivery vehicles have been
used successfully to deliver drugs at the site of the tumor.
This is facilitated by the enhanced permeability and retention
effect of tumors [20]. Passive tissue targeting formulations
are an accepted form of nanodrug delivery systems. Various
formulations have been created that are focused around the
anti-cancer drugs and its targeting ligands. As a result, a large
number of nanoparticle systems is available and proven to be
effective and are currently in clinical trials. Different nano-
material configurations include micelles, liposomes, dendri-
mers, nanoparticles, and macrostructures made of nanoscale
materials. Each of these has been used in various applications
and can be modified if needed.
Articular cartilage repair strategies can benefit from
intra-articular delivery of therapeutic nanoformulations on
multiple levels including: improvement in drug retention
time, improved bioavailability of drugs, high efficiency at low
concentrations, and reduced side effects due to the contain-
ment of drugs in the joint space.
To optimize the potential of nanomaterials for osteoarth-
ritis treatments, it is important to realize that the existing
nanomaterials require chemical adaptations, which are based
on our biological understanding of the synovial joint and
its articular cartilage. Therefore, we provide a combinatorial
view of both nanomaterials and the biological aspects of the
joint.
2. Micelles
Micelles are formed when an amphiphilic molecule (having
hydrophilic and hydrophobic domains) is dispersed in aque-
ous medium. The critical micelle concentration is the min-
imal concentration of the amphiphile in aqueous solution
necessary for micelle formation. When a poorly soluble drug
is added to this mixture, the hydrophobic domain entraps
the drug at its core and protects it from the aqueous medium.
The hydrophilic shell stabilizes the formedmicelle (Figure 2).
For micelles made of amphiphilic co-block polymers, the cri-
tical association constant (analogous to critical micelle con-
centration of surfactant micelles) is very low. This enables
continued stability of the micelle even after a large dilution in
vivo. The size of the polymeric micelles ranges approximately
from 10 nm to 100 nm [22]. Depending on the properties of
the amphiphile and drug payload, the size of the micelle var-
ies. Use of polymeric micelles as drug delivery vehicles
came into practice by preparation of doxorubicin-conjugated
block copolymer micelles [23]. The use of polymeric micelles
as drug delivery vehicles has become widely accepted and the
latest advances in this field have recently been reported [24].
Typically, polymeric micelles are made as injectable formu-
lations. Studies concerning polymeric micelles include, but
are not limited to, application in the fields of active target-
ing anticancer drugs to tumors [25], imaging of various
structures in vivo [26], and delivery of nucleic acids to cells
[27].
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Figure 2: Features of polymeric micelles [21]. An amphiphilic copolymer in aqueous medium forms a micelle where the hydrophobic
domains come together forming a core and hydrophilic domains forms the shell of the micelle. Hydrophobic drugs are entrapped in the
core. Reactive functional groups at the micelle surface can be used to couple ligands for targeted delivery. Reproduced with permission from
Elsevier.
Table 1: Polymeric micelle formulations in clinical trials [26].
Clinical phase Diameter Block copolymer Drug Tissue target
I/II
20–50 nm PEG-P(D,L-lactide) Paclitaxel
Pancreatic cancer in combination with gemcitabine
Ovarian cancer in combination with carboplatin
30 nm PEG-Pglu(cisplatin) Cisplatin Solid tumors
II
20 nm PEG-PGlu(SN-38) SN-38 Breast cancer
20–50 nm PEG-P(D,L-lactide) Paclitaxel
Pancreatic cancer
Non-small-cell lung cancer in combination with carboplatin
85 nm PEG-P(aspartate) Paclitaxel Advanced stomach cancer
III 22–27 nm Pluronic L61 and F127 Doxorubicin
Adenocarcinoma of oesophagus, gastroesophageal junction,
and stomach
IV 20–50 nm PEG-P(D,L-lactide) Paclitaxel Breast cancer
Micelles make excellent vehicles because of their struc-
tural similarity to adenovirus [28]. For example, the size of
animal viruses ranges from 20 to 100 nm, and these viral
particles deliver their genome into the cells after escaping the
clearance by kidneys and reticuloendothelial system. Viral
particles possess the property of cargo protection (viral gene)
by having supramolecular assemblies that provide an inner
core for cargo and outer shell (Capsid) made of biopolymers
that give the stealth-like properties to the particle. This
stealth-like property can also be seen as the biocompatibility
that is necessary for evading the patient’s immune system.
Moreover, the transfection efficiency of viral particles is as
well attributed to the presence of suitable ligands at the sur-
face for spatial recognition and timely disintegration of the
molecular assembly to deliver the payload. Interestingly,
micellar transport is analogous to the transport of cholesterol
by lipoproteins where the insoluble cholesterol in blood is
transported by vehicles of lipoproteins of varying sizes.
From this example, it is evident that micelles mimic
phenomena that occur commonly in mammals. Aforemen-
tioned structural similarities of micelles with the naturally
occurring nanoscale vehicles provide insight into the use of
polymeric micelles for application in drug delivery systems.
Many strategies to implement the stealth-like properties, tar-
geting properties, and stability have been tried ever since the
use of micelles in drug delivery was implicated. Stealth-like
property or biocompatibility can be easily achieved by the use
of hydrophilic, biocompatible polymers such as polyethylene
glycol (PEG), poly(N-vinyl pyrrolidone), poly(N-isopro-
pyl acrylamide) and poly(hydroxypropyl methacrylamide).
Among these hydrophilic shell forming polymers PEG is
most extensively used. It is nontoxic, hydrophilic, inert in
biological fluids and can be coupled to various chemical
groups for ligand attachment [29].
Most of the micelle formulations [26] that are currently
in various clinical trial phases contain PEG as the hydrophilic
segment. These formulations are able to deliver various drugs
to distinct tissue targets. They demonstrate reduced systemic
toxicity of the drugs and prolonged circulation times com-
pared to drugs without a nanocarrier. Some of the formula-
tions are listed in Table 1 [26]. These formulations do not
contain ligand that directs them towards a specific target.
Enhanced permeability and retention effects of tumors are
exploited in these cases where the micelles accumulate pre-
ferentially in tumor vasculature thus increasing the drug con-
centration in tumors. The robust nature of these formula-
tions in in vivo conditions and encouraging results from their
preceding in vitro studies has enabled these micelles to be
tested at various phases of clinical trials. This suggests that
these formulations, after being replaced with appropriate
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Table 2: Targeted micelle formulations.
Ligand type Ligand Target Copolymer Reference
Antibody
mAb 2C5
Nucleosome-restricted specificity for
different cancer cells
PEG-b-PE [54]
mAb C225 EGF receptor PEG-b-PG [55]
mAb HD39-SA CD22
Biotinylated PDMAEMA-b-
DMAEMA-BMA-PAA
[56]
Peptide
αvβ3 ligand
(cRGDfK)
αvβ3 integrin PEG-b-PCL [57]
VPAC2 Vasoactive intestinal peptide receptor DSPE-PEG3400-NHS [58]
Angiopep-2
Lipoprotein receptor-related protein
(LRP) present on the BBB
PE-PEG [59]
WYRGRL Collagen II α1 Pluronic F-127 [31]
Others
Folate Folate receptor
PLGA-b-PEG [60]
mPEG-b-PCL [61]
PEG3350-DSPE:
mPEG2300-DSPE(1 : 100)
[62]
Galactosamine Asialoglycoprotein receptor (ASGP-R) PCL67-PEEP36-CDI [63]
types of drugs, are suitable for use in drug delivery at dif-
ferent anatomical locations such as the synovial joints. Effi-
ciency of the modified formulations has to be validated
through appropriate studies. Micelles also have some disad-
vantages such as concerns over toxicity, storage stability, and
limited number of polymers for clinical use [30]. Controlled
delivery of hydrophobic drugs greatly benefits micelle for-
mulations, but for incorporation of hydrophilic drugs they
appear less suited. For these purposes, modification of the
polymeric building blocks might prove to be necessary.
Nonetheless, it is a promising direction to follow in order
to utilize the proven methodologies for applications that
need better drug administration routes. Table 2 summarizes
the ligands of targeted micelle formulations that have been
reported. The ligands can be divided into three categories,
namely, monoclonal antibodies, peptides, and others. Pref-
erential binding of a ligand to its receptor (overexpressed in
a diseased condition or unique to a cell population) is being
exploited to improve the targeting efficiency of micelles.
Similar approaches can be applied to target a specific com-
ponent of the synovial joint in order to prevent or block any
undesirable mechanism that could potentially initiate, prop-
agate, or exacerbate joint diseases such as osteoarthritis.
Some approaches have been described, such as the use of a
specific peptide that targets collagen II α1, WYRGRL, [31],
and antibodies against cleavage fragments of aggrecanase
[32].
3. Liposomes
Liposomes are spherical vesicles made of phospholipid bilay-
ers that are comparable to mammalian cell membranes.
Liposomes contain an aqueous compartment which can
carry molecules that are protected from the external environ-
ment. Methods of forming liposomes include dispersing
phospholipids in aqueous medium, high pressure extrusion,
sonication, detergent dialysis, and so forth [33]. The different
types of liposomes include small unilamellar vesicles
(∼100 nm) made of a single bilayer, large unilamellar vesicles
(200–800 nm), and multilamellar vesicles (500–5000 nm)
that contain several bilayers in a concentric manner
(Figure 3). The liposomes’ surface can be modified with
polymers to generate long circulating liposomes and or with
antibodies to create immunoliposomes that accumulate at
sites expressing the targeted antigen [34].
Drug delivery is one of the major fields where liposomes
are extensively studied. Consequently, a number of liposomal
formulations encapsulating drugs are studied in clinical trials
[36]. Liposomes also have been explored for gene delivery
[37], where cationic liposomes are made to facilitate the
interaction with the cell membranes and nucleic acids [38].
Targeted liposomal formulations using ligands such as folate
[39, 40], transferrin [41, 42], and RGD peptides [43] have
previously been reported. MRI and CT imaging applications
have also benefited by the use of liposomes carrying contrast
agents [44, 45]. Liposomes can be loaded with both magnetic
materials and therapeutic molecules to enable the magnetic-
field-assisted localization of these particles for imaging and
subsequent elicitation of therapeutic effect in the immediate
surroundings.
Surface modification using polymers such as PEG pro-
longs the circulation time of liposomes. This enables the lipo-
somes to escape the clearance by reticuloendothelial system
thereby providing better bioavailability. This is particularly
useful for injection into the joint cavity since it prevents the
opsonization of liposomal formulations by synovial com-
ponents. Other polymer coatings reported for this purpose
include poly-N-vinylpyrrolidones [46, 47], polyvinyl alcohol
[48], and branched oligoglycerols [49].
Intra-articular injection of a liposomal formulation con-
taining both dexamethasone and diclofenac has been shown
to be effective in reducing inflammation in knee joints of OA
rats [50]. This demonstrates that it is possible to intra-arti-
cularly inject a carrier that incorporates different drugs
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Figure 3: Classification of liposomes and their relative sizes. SUV: single unilamellar vesicles, MLV: multilamellar vesicles, LUV: large
unilamellar vesicles [35]. Reproduced with permission from Elsevier.
without loss of biological activity. This allows for targeting of
different tissues with distinct drug combinations in a straight
forward manner.
Advantages of using Liposomes include (1) excellent bio-
compatibility, (2) easy encapsulation of hydrophilic drugs
into their core compartment and hydrophobic drugs into
their lipid bilayer, (3) ability to effectively penetrate cell
membranes, (4) delivery of drugs into the cell compart-
ments, and (5) versatility in modifying the surface properties
in physical and chemical aspects by altering or introducing
new components into the lipid bilayer. The systemic use of
liposomes has drawbacks such as rapid clearance from the
blood, disintegration of the structure, and thereby release of
drugs at undesirable site and time. Although local injection
within a synovial joint might circumvent these drawbacks,
rapid clearance from the synovial fluid remains a challenge
for untargeted formulations.
In addition to traditional applications such as drug deliv-
ery, liposomes might be used to enhance joint lubrication.
Goldberg’s group reported that phosphatidylcholine lipo-
somes absorbed to negatively charged mica surfaces reduce
the coefficient of friction between surfaces [51, 52]. In other
words, absorption of these liposomes onto two negatively
charged surfaces results in less friction upon pressure than
the surfaces without these liposomes. This potentially means
that when these liposomes are injected into the synovial
joints, it can improve lubricity to the joints by binding to the
negatively charged cartilage surface. In addition, it has been
shown that the lactoferrin loaded positively charged lipo-
somal formulation had higher retention time in the joint
when compared to free injected lactoferrin in 24 hours. On
the other hand, negatively charged liposomes cleared more
rapidly than freely injected drugs [53]. Therefore, it is likely
that positively charged liposomes have a higher potential for
inflicting an effect in the synovial joint than the formulations
with negative or neutral charges. This indicates that specific
modifications of nanoparticles can be used to modulate tis-
sue retention times.
4. Dendrimers
Dendrimers are a relatively recently developed family of
macromolecules that has found its potential in a vast amount
of applications. Dendrimers are highly branched synthetic
structures with defined components: the core, the shell,
and the cavity. The dendrimer size depends on the number
of generations, that is, the number of layers it contains
(Figure 4). Stepwise increase in size is observed with each
generation of a dendrimer. In contrast, the number of func-
tional groups increases exponentially with each generation.
The amount of functional groups available in dendrimers is
much higher than its linear counterpart, when comparing a
linear polymeric chain and a dendrimer of a similar mole-
cular weight. Depending on the dendrimer’s generation, the
diameter and thus the structure and reactivity varies. As the
number of generations increases, steric hindrance of the sur-
face groups allows for only a limited number of chemical
groups to be added. This also depends on the property of the
chemical group required to be coupled to the dendrimer sur-
face. Nonetheless, dendrimers have a vast amount of reactive
groups compared to linear polymers.
Dendrimers are prepared in two different ways. They can
be synthesized stepwise from the core diverging to the shell
[64] or the branched shell components can be made first and
then coupled to a core to form a dendrimer [65]. Click chem-
istry [66] and thiol-ene chemistry [67] can be used to syn-
thesize different dendrimers. Classic examples of dendrimers
are polyamidoamine (PAMAM), poly(L-lysine) (PLL), poly-
propylenimine (PPI), poly(2,2-bis(hydroxymethyl) propion-
ic acid (bis-MPA), and phosphorous-based dendrimers [68,
69].
The structure and composition of dendrimers can be
tightly controlled resulting in the monodispersity of the final
product. Monodispersed macromolecules have large num-
bers of functional groups at their surface, which allows for
further defined chemical modifications. In case an antibody
is used for such modification, the chemically modified
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Figure 4: Graphical presentation of PAMAM dendrimers from core to generation G = 7 showing the linear increase in diameter and expon-
ential growth of the number of surface groups. In blue, the surface groups are depicted and the core is depicted in yellow/orange [84].
Reproduced with permission from Elsevier.
dendrimer shows much higher affinities towards its corre-
sponding substrate as compared to a macromolecule without
ligand [70]. Properties such as high affinity towards substrate
and multivalency make dendrimers attractive candidates for
targeted delivery vehicles. Moreover, higher generation den-
drimers contain internal cavities, which allows for payload
to be loaded and protected from the environment until the
branches of the dendrimer fall apart.
Although encapsulation of drugs into dendrimers is
achieved, the efficiency of drug release remains to be improv-
ed. A few studies have reported that the release of more
than 70% encapsulated drugs is in the range of a couple of
hours in phosphate buffered saline [71]. Encapsulated drugs
in other formulations behave in largely similar manners
[72, 73]. However, the release rate can be highly controlled by
the covalent coupling of drugs to the dendrimers and these
formulations are called prodrugs. Dendrimers such as
PAMAM and PPI have been successfully combined with vari-
ous anticancer, anti-inflammatory, and antimicrobial drugs
either by physical encapsulation or chemical coupling. De-
tailed information about these drug-dendrimer formulations
can be found in the literature [74]. It is essential to know that
the type of linkers used to couple the dendrimer and drug
has an influence in the rate of the drug release. For example,
using PAMAM coupled with paclitaxel using two different
linkers such as succinic acid and glutaric acid shows that
the former conjugate had a half-life of about 10 hours and
the latter did not show a significant drug release in PBS for
a week. Nonetheless, a different study showed encouraging
results when a glutaric acid linker was used with a different
type of dendrimer [75].
Similar to other nanoscale formulations, inclusion of tar-
geting ligands to the surface of dendrimers enhanced the
accumulation of targeted dendrimers up to 20-fold as
compared to nontargeted dendrimers [76]. Similar targeted
dendrimer formulations have been published [77, 78]. Den-
drimers are proven to be effective for transfection of genes
into cells [79, 80]. Due to the presence of cationic functional
groups dendrimers complexed with DNA or RNA fragments
enter the cells by receptor-mediated endocytosis and by other
routes. The increase in positive charge on the dendrimer sur-
face can cause significant toxicity to the cells and also poor
efficiency of transfection. Cationic groups can be neutralized
by coupling them with PEG like materials, and this has been
proven to be effective in reducing toxicity and improving
transfection efficiencies [80, 81]. Another interesting appli-
cation of dendrimers that falls under the scope of this paper
is their use in MRI imaging of articular cartilage. Nitroxides,
a class of contrasting agents that gain positive charge under
physiological pH, were linked to PAMAM-dendrimers. These
dendrimers are shown to provide information about the
articular surface, and potentially also about the distribution
of proteoglycans in degenerated cartilage [82]. Absorption of
the positively charged dendrimer-Nitroxide by the cartilage
tissue enables high contrast in MRI when compared to free
nitroxides and gadopentetate dimeglumine. This might
prove useful in quantification of regional proteoglycan loss
in degenerating joints.
Properties such as cell and ECM penetration make den-
drimers attractive candidates for transporting OA drugs to
the chondrocytes and cartilage matrix. Recently, the feasi-
bility and potency of dendrimer-based joint treatments has
been demonstrated in two establishedmousemodels of auto-
immune arthritis [83]. The intravenous injection of phos-
phorous-based dendrimers decorated with azabisphospho-
nate (ABP) groups at their surface-reduced expression of
proinflammatory cytokines and increased production of
anti-inflammatory cytokines. In addition, these dendrimers
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potently inhibited bone resorption and differentiation of
monocytes and osteoclasts in vitro. ABP-capped dendrimers
inhibited the development of rheumatoid arthritis and re-
versed paw swelling, clinical scores, and bone erosion in the
mice models. Inflammation was completely inhibited show-
ing near normal synovial membranes and intact cartilage
after a few weeks. Moreover, dendrimer ABP reduced mono-
cyte differentiation in ex vivo explants of synovial tissue from
patients undergoing arthroplastic surgery. This study showed
that the ABP-capped dendrimer is capable of reducing pro-
inflammatory factors as well as osteoclast activity both in
vivo in mice as well as in vitro in human cells [83], clear-
ly demonstrating the clinical potential of dendrimer-based
therapies for joint diseases. Although the potential of den-
drimers to target specific joint components is promising,
much knowledge remains to be gained before dendrimers
can be routinely used in a clinical setting. This is at least part-
ly due to our limited knowledge on in vivo side-effects, time
consuming synthesis methods, and the non-bio-degradable
nature of many dendrimers.
5. Other Nanoparticles
The term nanoparticle is ambiguously used by different
groups. All particles at the nanometer scale regardless of their
unique chemical, physical, and structural properties could
potentially be considered as a nanoparticle. In this paper we
will only address the solid nanoparticle formulationsmade of
polymeric materials that do not share physical similarities
with other nanomaterials described in this paper. We do not
focus on metallic and ceramic nanoparticles as their material
properties are likely to further damage the affected joint by
erosion.
Polymeric nanoparticles are colloidal materials with sizes
ranging from few a nanometers to a few hundred nanome-
ters. The size of the nanoparticles is variable according the
type of polymer, bioactive agent, and processing method.
Different processing methods include solvent evaporation,
interfacial deposition, nanoprecipitation, double emulsion,
and spray drying. Biodegradable polymers such as poly-D,L-
lactide-co-glycolide (PLGA), polylactic acid (PLA), poly-ε-
caprolactone (PCL), chitosan, and gelatin are commonly
used for nanoparticle preparation. These polymers are high-
ly biocompatible and are used in various drug delivery ap-
plications, including cancer and cardiovascular diseases [85,
86]. Drugs are commonly encapsulated in nanoparticles us-
ing various methods. For example, the drug can be added to
the polymer solution during synthesis or the nanoparticles
are synthesized and then incubated in a drug solution to
absorb the drug [87]. The drug release profile is highly de-
pendent on the polymer composition. The possible release
mechanisms include (1) desorption of the bound drug, (2)
release by diffusion, (3) release by polymer erosion, (4) or
a combination of the above-mentioned mechanisms. Please
note that the drug release profile can be effectively tuned by
changing the molecular weight of the polymer [88].
Despite the biocompatibility of the commonly used poly-
mers, it is essential to modify the nanoparticle surface with
agents that provide stealth properties that prevent recogni-
tion of the patient’s immune system. This enables a prolong-
ed retention of drug-loaded nanoparticles in both systemic
circulation and intra-articular space. Indeed, PEG surface
modified nanoparticles showed a prolonged circulation time
compared to nonmodified nanoparticles [89, 90]. Polymers
such as PLA and PLGA have been approved for use in hu-
mans by the US Food and Drug administration. Therefore,
the use of nanoparticles synthesized from these polymers is
widely accepted and has previously been reported in several
research fields that include gene therapy [91], biomedical
imaging [92], drug delivery [93], and cancer therapy [94].
Nanoparticles possess advantages such as biodegradabil-
ity, controllable size, variety of synthesis methods, and ver-
satility in surface functional groups for coupling of ligands.
However, the drug release profile of nanoparticles is typically
based on a burst release of the encapsulate drugs. Moreover,
nanoparticles are sensitive to opsonization and clearance by
reticuloendothelial system.
Owing to the versatile nature of nanoparticles, multiple
facets of OA can be addressed by incorporating different
drugs into nanoparticles or by incorporating different drugs
in different nanoparticles. The potential that nanoparticles
hold for the OA treatment is comparable to that of other
nanoformulations discussed in this paper.
6. Potential Formulations for
Osteoarthritis Drugs
Current OA drug therapy recommends the use of non-
steroidal anti-inflammatory drugs (NSAIDs) and cyclooxy-
genase-2 inhibitors. NSAIDs are typically anti-inflammatory,
analgesic, and antipyretic agents that act by nonspecifically
inhibiting the effects of cyclooxygenase 1 (COX-1) and COX-
2 enzymes, resulting in pain relief. Commonly recommended
NSAIDs are Paracetamol, Ibuprofen, and Celecoxib. COX-
2 mediates inflammation in response to appropriate stimuli
[95] and COX-2 expression is observed in degrading joints
for which COX-2 inhibitors are widely prescribed. These
drugs alleviate pain and improve OA therapy management
for a short time span. Use of these drugs is associated with
complications such as cardiovascular side effects and gastro-
intestinal toxicity [96]. Consequently, low doses of these
drugs are recommended at the clinical setting. Although
topical application of these drugs is possible, they are not
potent and cause skin irritation. Besides NSAIDs and COX-
2 inhibitors, other types of drugs such as cannabinoids, cap-
saicin analogs, antidepressants, antagonists of kainite recep-
tor, and Bradykinin and antibodies against nerve growth fac-
tor are being suggested for OA symptoms and are currently
being investigated [97]. Moreover, experimental drugs such
as glucosamine sulfate [98], chondroitin sulfate [99], and
diacerein [100] have been shown to provide alleviation of
symptoms and to have disease modifying effects. Despite the
introduction of new compounds, the systemic delivery of
drugs is likely also to cause side effects, which are not accep-
table for treatment of a nonlife threatening disease with re-
latively mild complaints particularly in an early stage of
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Table 3: Proposed assignment of different nanocarriers for delivery of active drugs to different targets within a synovial joint.
Target Desired properties of nanocarrier Potentially suitable nanocarrier
Cartilage matrix
(i) Size smaller than 38 nm∗
(ii) Positive surface charge
(iii) Ability to couple peptide ligands (WYRGRL) to target collagen II α1
Micelles, Dendrimers
Subchondral bone
(i) Size smaller than 38 nm∗
(ii) Positive surface charge
(iii) Ability to couple peptide ligands (WYRGRL) to target collagen II α1 to
make ECM as a drug reservoir for drugs that can reach subchondral bone
in case of early OA
(iv) Ability to target hydroxyapatite of subchondral bone in case of advance
OA where subchondral bone is exposed due to cartilage degradation
Micelles, Dendrimers
Cartilage surface
(i) Variable sizes can be used but if penetration into cartilage has to be
avoided, sizes greater than 60 nm are recommended
(ii) Positive surface charge
(iii) Ability to couple antibodies against epitopes of cartilage degradations
such as VDIPEN and NITEGE
Liposomes, Dendrimers of higher
generation, Micelles, Nanoparticles
Synovial membrane
(i) Variable size can be used but if penetration into cartilage has to be
avoided, size greater than 60 nm is recommended
(ii) Ability to retain in intra-articular space with a targeting aspect towards
a synovial joint component and subsequent uptake by synovial fibroblast
Liposomes, Dendrimers of higher
generation, Micelles, Nanoparticles
Intra articular space
(i) Variable size can be used but if penetration into cartilage has to be
avoided, sizes greater than 60 nm are recommended
(ii) Ability to form complexes with synovial fluid components that can help
in retention of nanocarrier in intra-articular space
Liposomes, Dendrimers of higher
generation, Micelles, Nanoparticles
Infrapatellar fat pad (i) Lipophilic properties that allow preferential absorption by fat tissue
Liposomes, Dendrimers of higher
generation, Micelles, Nanoparticles
∗
38 nm is the smallest size proven to penetrate articular cartilage. However, based the collagen mesh size, nanoparticles up to 60 nm might penetrate the
cartilage.
the disease. It is important to realize that the joints are
amenable for intra-articular injections. Therefore, it is intui-
tive that restriction of such drugs to synovial joint eliminates
these side effects. The lack of an adequate delivery system
prevents potentially beneficial disease modifying drugs from
routine clinical use. For example, inhibiting the activity of
p38 MAPK, a signal transduction kinase molecule, can pre-
vent cartilage degeneration and provide pain relief [101,
102]. Several p38 MAPK inhibiting drugs are identified and
have demonstrated disease modifying effects in various clin-
ical trials. However, these drugs cause cardiac, neuronal, and
hepatic complications, which prevent the routine systemic
use of these drugs [103]. These side effects would be omitted
when these drugs are used with an adaptive drug delivery sys-
tem that delivers and retains the active drugs within the tis-
sues of the synovial joint. Moreover, such approaches can be
used to target multiple signaling pathways in the joint.
Most of the nanoformulations in clinical trials are not
target specific. With this in mind, it is to be noted that par-
ticles smaller than 5 μm are rapidly cleared, as the synovial
joint lacks a basement membrane [104]. The therapeutic effi-
ciency of NSAIDs nanoformulations can be improved by en-
hancing its containment in the synovial joint. One of the
ways to improve the retention of these formulations is by the
use of positively charged carriers, which prolong the reten-
tion time within the synovial joint [53]. Therefore, it can be
anticipated that drug efficacy can be improved with minimal
side effects and lower drug dosages upon adapting the
existing technologies. Consequently, the amounts of the drug
able to leak into the systemic circulation will be too low to
elicit side effects in other tissues. Moreover, as lower amounts
of drugs are required to obtain a similar effect it may improve
cost-effectiveness of osteoarthritis drugs.
Within the synovial joint, there are different targets that
can be (in)activated to regain control over the catabolic shift.
Importantly, the ability to reach the precise anatomical loca-
tion of these targets will largely determine the therapeutic
success. For example, the cellular targets could be on the cell
surface, cytosol, nucleus, or intercellular space. These targets
include inflammatory cytokines [10], signal transduction
pathways [16], gene expression [105], and proteolytic
enzymes [106]. The main challenge in intra-articular drug
delivery is to prolong the retention time of drugs within the
synovial joint. The versatile nature of the different nanoscale
carriers makes them highly suitable for targeting and retain-
ing drugs at different loci of the synovial joint (Table 3). For
specific osteoarthritis drugs, it may prove unnecessary to
directly target cells as the extracellular matrix can potentially
be utilized as a drug reservoir. Drugs can be released in the
vicinity of the cell and still be available for cellular uptake.
This approach is able to deliver a higher amount of drug over
a prolonged period of time compared to cell-targeted ap-
proaches. In 2008, Rothenburg et al. suggested using a car-
tilage targeted system in which a nanoparticle was coupled
to a small peptide fragment that binds collagen IIa1, which
resulted in effective targeting of articular cartilage [31].
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Moreover, antibodies that bind epitopes of cartilage degra-
dation such as VDIPEN and NITEGE could be used to target
degrading cartilage [32]. OA is associated with changes in the
subchondral bone, and it is currently a challenge to effec-
tively deliver drugs to this tissue. Using the extracellular
matrix as a drug reservoir might overcome this hurdle. It is
important to realize that the mesh size of collagen II fibrillar
networks is approximately 60 nm [107], and the spacing
between side chains of the proteoglycan network is approxi-
mately 20 nm [108]. Consequently, only nanoparticles of suf-
ficiently small size allow for the penetration into the cartil-
aginous matrix. Indeed, Rothenfluh et al. showed that nano-
particles of 38 nm penetrated the cartilage matrix, while
nanoparticles of 98 nm could not [31]. During the early
stages of OA, collagen II can be targeted for both cartilage
and subchondral bone. However, in advanced stages the sub-
chondral bone is exposed to the intra-articular space due to
cartilage erosion. In such cases, hydroxyapatite can be target-
ed for the nanoparticles to reach subchondral bone. Further-
more, a degree of positive charge could potentially enable the
nanocarrier to interact with cartilage matrix. The negative
charge provided by sulfated proteoglycans would allow for
the electrostatic interaction between the nanocarrier and the
matrix.
Anabolic triggers are typically products of articular car-
tilage, but the catabolic triggers that degrade the articular
cartilage are derived from multiple tissues of the joint. The
tissues include articular cartilage, subchondral bone, syn-
ovium, meniscus, and the infrapatellar fat pad [109]. As a
consequence, it remains questionable whether targeting a
single symptom or tissue would eventually prove sufficient in
treatment of OA. It may be argued that as multiple compo-
nents of the joint are involved in OA pathology, each with
different mechanisms of action, a strategy that aims at dif-
ferent mechanisms and tissues might prove inevitable for
therapeutic success in treating OA. Nanomaterials are able
to provide a highly controllable platform that allows local
delivery of drug combinations to target each of these tissues
by injecting a mixture of specifically adapted nanoparticles.
To target distinct tissues, different nanomaterials can be
functionalized with appropriate ligands. Each nanomaterial
can contain a combination of drugs, peptide, gene fragments,
or antibodies to perform a specific function within the tar-
geted tissue. To design such amultifactorial drug delivery sys-
tem, the following factors should be taken into account: (1)
amounts and types of drugs required, (2) type of carrier
suitable for the drugs, (3) the carriers ability to reach the
target with respect to size, charge, and so forth, (4) type of li-
gand required for targeting, (5) release profile of the drug,
and (6) fate of the carrier after drug release.
The synovial membrane and infrapatellar fat pad contri-
bute to OA by secreting factors that are able to degrade car-
tilage [10]. Therefore, they can be considered as interesting
therapeutic targets. For example, Inflammation of the syno-
vial membrane is associated withOA [110]. Existing evidence
suggests that inflammatory cytokines, for example, IL-4 and
IL-13, proteolytic enzymes—for example, MMP’s and
ADAMTS—pain mediators, and nitrous oxide are being
released from the inflamed synovial membrane. This
ultimately leads to cartilage degradation. Moreover, chronic
synovitis is associated with enhanced vascularity of the tissue
that propagates the infiltration of macrophages. This per-
petuates the inflammation in the synovial membrane. There-
fore, it might be possible to prevent or slow down OA pro-
gression by blocking the catabolic trigger from the synovial
membrane. Any untargeted nanocarrier formulation could
potentially be used to deliver drugs to the synovial mem-
brane. Due to the increased vascularity and recruitment of
macrophages, the internalization of nanocarriers is enhanc-
ed. Nontargeted particles will be cleared by the lymphatic
drainage. Chronic synovitis impairs the lymphatic drainage,
which is likely to help retain the nanocarriers within the joint
space.
Finally, it is important to realize that nanomaterials con-
tain possible therapeutic potentials that are nondrug based.
For example, loss of lubrication between the cartilage sur-
faces could potentially lead to stress-induced arthritis. Treat-
ment using the positively liposomal formulation by Goldberg
et al. [52] can be used to append joint lubrication. In some
cases, the synovial fluid could also be used as a reservoir of
nanoparticle formulations.
7. Conclusion
The notion that nanomaterials can be used for drug delivery
is well established. However, its utilization remains to be fully
integrated in many areas of investigation including the field
of osteoarthritis research. Local delivery by nanomaterials
can potentially limit or even prevent current side-effects of
OA drugs. Osteoarthritis is a multitissue disease, and nano-
materials are an ideal platform to design combinatorial drug
therapies that stimulate or inhibit specific pathways in tar-
geted tissues. Straightforward adaptations to the existing
technologies can provide the necessarymodifications to opti-
mize osteoarthritis drug delivery and improve the therapeu-
tic outcomes.
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